Welcome to our dedicated page for U S Physical Therapy SEC filings (Ticker: USPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
U.S. Physical Therapy, Inc. (USPH) files a range of reports with the U.S. Securities and Exchange Commission that document its operations as a national operator of outpatient physical therapy clinics and provider of industrial injury prevention services. These SEC filings provide detail on its physical therapy operations segment, industrial injury prevention services, clinic additions and closures, financial performance, and capital allocation decisions.
On this Stock Titan page, investors can review U.S. Physical Therapy’s current reports on Form 8-K, which have recently covered topics such as acquisitions of multi-clinic physical therapy practices and management services companies, quarterly earnings results, dividend declarations, investor presentations, and research reports. For example, the company has filed 8-Ks describing acquisitions of a three-clinic physical therapy practice and a physical therapy management services company that manages a practice with eight clinic locations, as well as 8-Ks reporting results for specific quarters and announcing quarterly cash dividends.
In addition to 8-Ks, U.S. Physical Therapy files annual reports on Form 10-K and quarterly reports on Form 10-Q, which provide segment information for physical therapy operations and industrial injury prevention services, along with discussions of revenue, operating costs, gross profit, and key operating metrics such as total patient visits and net rate per patient visit. These filings also include information about the company’s credit facilities, interest expense, and tax provisions.
Stock Titan enhances access to these documents by offering real-time updates from the SEC’s EDGAR system and AI-powered summaries that explain the contents of lengthy filings. Users can quickly see the main points from U.S. Physical Therapy’s 10-K and 10-Q reports, as well as key disclosures from 8-Ks related to acquisitions, earnings, and dividends. This page also serves as a starting point for reviewing any insider transaction reports on Form 4 that may be filed for USPH, alongside the company’s broader regulatory history.
US Physical Therapy Inc (USPH) filed a Form 144 notifying a proposed sale of 2,000 Class A common shares through J.P. Morgan Securities LLC on the NYSE, with an aggregate market value of $169,570.50. The filing shows those shares were acquired by the seller through vesting of restricted stock awards granted between 8/16/2021 and 2/24/2025, received in three vesting events on 7/01/2024 (1,045 shares), 10/01/2024 (305 shares), and 1/01/2025 (650 shares). The proposed approximate date of sale is 08/19/2025. The filer certifies they are not aware of undisclosed material adverse information about the issuer.
Three institutional filers disclosed beneficial ownership of US Physical Therapy ordinary shares. Kayne Anderson Rudnick Investment Management, LLC reports beneficial ownership of 1,486,334 shares, representing 9.8% of the class. Virtus Investment Advisers, LLC reports 1,042,658 shares (6.9%) and Virtus Equity Trust on behalf of Virtus KAR Small-Cap Growth Fund reports 975,582 shares (6.4%).
The filing details voting and dispositive power: Kayne Anderson reports 417,216 shares with sole voting power and 443,348 shares with sole dispositive power, with larger amounts held in shared voting/dispositive arrangements. The filing also certifies the shares are held in the ordinary course of business and not to influence control, and notes that amounts reported for the Virtus entities are included in the amounts reported by Kayne Anderson Rudnick on this Schedule 13G.
Reeve Graham D., Chief Operating Officer of U S Physical Therapy, Inc. (USPH), reported an insider sale on 08/11/2025. The Form 4 discloses a disposition of 1,792 shares of common stock at a price of $86.57 per share. Following the sale, the filing shows 22,246 shares beneficially owned directly and 1,808 shares held indirectly through the Reeve Trust.
The filing also details that 17,244 shares are restricted stock granted under the companys 2003 Stock Incentive Plan, with a specified vesting schedule listing dates and tranche sizes through March 6, 2029, conditional on continued employment.
U.S. Physical Therapy, Inc. (NYSE: USPH) reported a Regulation FD disclosure in a Form 8-K stating that on August 12, 2025 the company updated its investor presentation. The presentation provides an overview of the company and is posted on the company website under Investor Relations.
The filing identifies Exhibit 99.1 as the "USPH Investor's Presentation for the Three and Six months Ended June 30, 2025." The company expressly states the information is furnished, not filed, and therefore is not subject to Section 18 liabilities or automatically incorporated by reference into registration statements.
US Physical Therapy (USPH) reported a proposed sale of 1,792 shares of Class A common stock on the NYSE through J.P. Morgan Securities, with an aggregate market value of $155,124.48. The filing states the shares were acquired on 05/20/2025 by vesting of restricted stock grants (grants issued from 08/16/2021 to 02/24/2025) and lists an approximate sale date of 08/11/2025 with payment in cash.
Against total outstanding shares of 15,190,000, the 1,792-share notice represents about 0.0118% of the company’s shares outstanding. The filer reported no securities sold in the past three months. The form includes the required compliance representation under Rule 144 and identifies J.P. Morgan Securities LLC as the broker.
U.S. Physical Therapy, Inc. (NYSE: USPH) hosted a conference call and webcast on August 7, 2025 to discuss results for the three and six months ended June 30, 2025. The company furnished the conference call transcript as Exhibit 99.1 to this Current Report and stated the materials are furnished, not filed, so they are not subject to Section 18 liabilities and are not incorporated by reference unless expressly provided.
This 8-K itself does not present financial statements or earnings figures; it makes management commentary and the call transcript available to investors as a supplemental disclosure.
Q2 2025 performance (USPH)
- Net revenue rose 18% YoY to $197.3 m; six-month revenue $381.1 m (+18%).
- Net income attributable to shareholders jumped 65% to $12.4 m; diluted EPS $0.58 versus $0.47.
- Operating income improved 60% to $24.9 m; margin expanded to 12.6% (9.3% LY) aided by a $0.8 m gain on contingent earn-out revaluation.
- Gross margin inched up to 21.1% from 20.3% despite higher salary and rent expense.
- Cash from operations YTD $30.2 m (-10%); cash balance fell to $34.1 m after $6.9 m of acquisitions and $13.7 m in dividends.
- Debt profile: revolver borrowings increased to $24.5 m (11.0 m YE); term loan reduced to $127.1 m. Interest expense up 22% YoY.
- Clinic count reached 768 (+46 YoY) after 6 openings, 4 closures and two bolt-on deals (3 clinics + home-care business).
- Equity climbed to $500.8 m; quarterly dividend lifted to $0.45.
Other notes: No impairment triggers were identified. New U.S. tax legislation signed 4 Jul 25 is not yet reflected. Management continues acquisitive growth strategy.